Literature DB >> 26650014

Acute Generalized Pustular Psoriasis Treated With the IL-17A Antibody Secukinumab.

Alexander Böhner1, Sophie Roenneberg1, Kilian Eyerich1, Bernadette Eberlein1, Tilo Biedermann1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26650014     DOI: 10.1001/jamadermatol.2015.4686

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


× No keyword cloud information.
  5 in total

1.  IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis.

Authors:  Andrew Johnston; Xianying Xing; Liza Wolterink; Drew H Barnes; ZhiQiang Yin; Laura Reingold; J Michelle Kahlenberg; Paul W Harms; Johann E Gudjonsson
Journal:  J Allergy Clin Immunol       Date:  2016-12-31       Impact factor: 10.793

2.  Secukinumab in Generalized Pustular Psoriasis.

Authors:  Shraddha Madanagobalane
Journal:  Indian Dermatol Online J       Date:  2018 Nov-Dec

Review 3.  Pustular psoriasis: pathophysiology and current treatment perspectives.

Authors:  Katie E Benjegerdes; Kimberly Hyde; Dario Kivelevitch; Bobbak Mansouri
Journal:  Psoriasis (Auckl)       Date:  2016-09-12

4.  Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies.

Authors:  Rajkumar Ganesan; Ernest L Raymond; Detlev Mennerich; Joseph R Woska; Gary Caviness; Christine Grimaldi; Jennifer Ahlberg; Rocio Perez; Simon Roberts; Danlin Yang; Kavita Jerath; Kristopher Truncali; Lee Frego; Eliud Sepulveda; Priyanka Gupta; Su-Ellen Brown; Michael D Howell; Keith A Canada; Rachel Kroe-Barrett; Jay S Fine; Sanjaya Singh; M Lamine Mbow
Journal:  MAbs       Date:  2017-07-20       Impact factor: 5.857

5.  Recalcitrant annular pustular psoriasis associated with psoriatic arthritis successfully treated with secukinumab.

Authors:  María Herrero-Moyano; Tania Marusia Capusan; Constanza Martínez-Mera; Mar Llamas-Velasco; Esteban Daudén
Journal:  JAAD Case Rep       Date:  2018-09-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.